ArticleThe open medicinal chemistry journal2011
Structures, targets and recent approaches in anti-leishmanial drug discovery and development.
Article in The open medicinal chemistry journal, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 1 synthesis or guideline pooled it, 98 citations in OpenAlex.
- Interventions for American cutaneous and mucocutaneous leishmaniasis: a systematic review update.PloS one · 2013Pooled it
- Tranylcypromine: a promising repurposed drug against Leishmaniases.Frontiers in microbiology · 2025Article
- Advancing Insights Into Visceral Leishmaniasis: Challenges, Innovations, and Future Directions in Global Disease Management.Journal of parasitology research · 2025Article
- Lipid and fatty acid metabolism in trypanosomatids.Microbial cell (Graz, Austria) · 2021Review
- Pharmacokinetic / pharmacodynamic relationships of liposomal amphotericin B and miltefosine in experimental visceral leishmaniasis.PLoS neglected tropical diseases · 2021Article
- Development and Characterization of PLGA Nanoparticles Containing 17-DMAG, an Hsp90 Inhibitor.Frontiers in chemistry · 2021Article
- Evaluation of the Pharmacophoric Role of the O-O Bond in Synthetic Antileishmanial Compounds: Comparison between 1,2-Dioxanes and Tetrahydropyrans.Journal of medicinal chemistry · 2020Article
- Activation of artemisinin and heme degradation in Leishmania tarentolae promastigotes: A possible link.Biochemical pharmacology · 2020Article
- In vivo antileishmanial activity of Annona mucosa extracts.Revista da Sociedade Brasileira de Medicina Tropical · 2020Article
- Article
- Pharmacodynamics and cellular accumulation of amphotericin B and miltefosine in Leishmania donovani-infected primary macrophages.The Journal of antimicrobial chemotherapy · 2018Article
- Histopathological and immunohistochemical characterisation of hepatic granulomas in Leishmania donovani-infected BALB/c mice: a time-course study.Parasites & vectors · 2018Article
- Leishmanicidal effect of antiparasitic photodynamic therapy-ApPDT on infected macrophages.Lasers in medical science · 2017Article
- Library of Seleno-Compounds as Novel Agents against Leishmania Species.Antimicrobial agents and chemotherapy · 2017Article
- Snapshot Profiling of the Antileishmanial Potency of Lead Compounds and Drug Candidates against Intracellular Leishmania donovani Amastigotes, with a Focus on Human-Derived Host Cells.Antimicrobial agents and chemotherapy · 2017Article
- In vitro anti-Leishmania activity of tetracyclic iridoids from Morinda lucida, benth.Tropical medicine and health · 2016Article
- Plant-derived compounds in treatment of leishmaniasis.Iranian journal of veterinary research · 2015Review
- Duplex quantitative Reverse-Transcriptase PCR for simultaneous assessment of drug activity against Leishmania intracellular amastigotes and their host cells.International journal for parasitology. Drugs and drug resistance · 2014Article
- Article
- Drug resistance in leishmaniasis: Newer developments.Tropical parasitology · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Recent years have seen a significant improvement in available treatment options for leishmaniasis. Two new drugs, miltefosine and paromomycin, have been registered for the treatment of visceral leishmaniasis (VL) in India since 2002. Combination therapy is now explored in clinical trials as a new treatment approach for VL to reduce the length of treatment and potentially prevent selection of resistant parasites. However there is still a need for new drugs due to safety, resistance, stability and cost issues with existing therapies. The search for topical treatments for cutaneous leishmaniasis (CL) is ongoing. This review gives a brief overview of recent developments and approaches in anti-leishmanial drug discovery and development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.